P

Patient-Led Research Collaborative

@patientled

7,983

Followers

1,598

Following

305

Posts

N/A

Reels

5

Highlights

12/0

Photos/Videos in last 12

Bio

We are a self-organized group of #LongCOVID patients and patients of associated illnesses such as #MECFS and #POTS working on patient-led research.

-

Avg likes

-

Avg comments

-

Engagement

0.2/wk

Posting

Likes and comments are still being collected for this account. Check back shortly.

Recent posts

PLRC is kicking off a summer fundraiser to help sustain our work and fund new projects that will improve clinical trials and biomarkers! You can help us do this by making a donation, sharing our posts, and forwarding the emails you receive to folks in your network. Find the link to donate in our story and bio! Six years into the pandemic — and for many of us, this illness — clinical trials, diagnostics, and treatments are the top priority. We know that Long COVID is not mysterious, there are hundreds of documented abnormalities associated with disease, and the time has come to strengthen clinical trials, biomarkers, and treatment identification. PLRC has been working on advancing clinical trials for years, and have recently written about outcome selection and negative trial results. But we need to push the field further! Image descriptions: [Slide 1] PLRC is currently fundraising for two projects that will improve clinical trials and biomarkers. [Slide 2] 1. At-home biomarkers of post-exertional malaise (PEM) Why PEM is one of the most debilitating components of Long Covid, and one of the hardest states to measure. What A decentralized study of at-home PEM biomarkers — using wearable devices measuring relevant markers like lactate, cerebral blood flow, glucose, and muscle oxygenation — to test whether PEM can be detected and quantified. Impact A biomarker for PEM offers researchers an objective clinical trial endpoint, and additionally flags when PEM is confounding other tests or imaging results. [Slide 3] Why Despite an enormous amount of research on Long COVID symptom frequency, almost no research has been done on which symptoms patients find the most debilitating. This leads to researchers designing studies that confound the uniqueness of symptoms with debilitation. What We have a dataset of over 4,000 patients each ranking their most debilitating symptoms. We would like to clean, analyze, and publish this data. Impact This data will help us to know which symptoms to focus on when choosing clinical trial drug candidates, as well as appropriate endpoints and outcome measures. Continued in comments... 20 Jul 2026 The Patient-Led Research Collaborative and the RTHM Clinic are excited to release the #LongCovid Treatment Guide. This guide is meant to spark meaningful conversations between patients and their clinicians about treatment options that could become part of a personalized care plan. The guide focuses on a set of 24 prescription medications, while including a limited number of supplements, over the counter medications, procedures, and lifestyle strategies for breadth. If you’d like a direct link to the guide, comment #guide below! Since there are no FDA-approved treatments for Long COVID, all pharmaceutical options are off-label, supported by clinical data, as well as patient and clinician expertise. One of our intentions was to gather this evidence all in one place so that patients and clinicians can make decisions informed by evidence. The Treatment Guide is not an exhaustive list, nor is it intended to serve as individualized medical advice. To support the use of listed treatments, we used both data from early clinical studies in Long COVID and data from infection-associated chronic conditions (IACCs) that are common in this patient population, such as postural-orthostatic tachycardia syndrome (POTS) and mast cell activation. Our decision to include a treatment was guided by existing evidence from the literature and the patient community, clinician expertise, as well as the Harvard/Stanford TREATME study organized by Dr. Martha Eckey, PharmD. We also prioritized listing treatments that were backed by other clinical treatment guides of other IACCs. Thus, the Treatment Guide is an evidence-based resource hub that can help inform clinicians and patients about treatments that could be tried today. We hope this resource can help patients evaluate the options available to them and can inform clinicians on the supporting evidence for off-label treatment options for Long COVID. 11 Mar 2026 For #LongCovid Awareness Day, we're releasing the 2026 Long COVID Fact Sheet! This is a list of key statistics about Long COVID, using recent data to reflect contemporary risks. We hope this will be useful for journalists, policymakers, patients, & others! Link in bio: https://patientresearchcovid19.com/2026-long-covi d-fact-sheet/ 15 Mar 2026 🔬 New research, made possible by Visible members who volunteered their data. We’re proud to share that the findings are now published in Nature Portfolio’s Scientific Reports. Led by Rachel Robles of the Patient-Led Research Collaborative and the University of Bern, alongside researchers from UCSF and Visible, the study looks at how Covid reinfections affect people living with Long Covid and/or ME/CFS. Detailed, day-to-day health data helps researchers understand these illnesses in ways a few clinic visits can’t. This is the kind of evidence that can lead to better care. Thank you to every member who chose to contribute. This research wouldn’t have been possible without you 💙 Swipe for the key findings, and read more via the link in our bio. 10 Nov 2026 Comment “Register” to get a direct message to the registration link of the webinar. Join us for our End-Of-Year Roundtable Webinar on Clinical Trials, Biomarkers and Equitable Care in Long COVID, a moderated discussion about recent advances and future research plans led and supported by PLRC and our research collaborators.” Speakers include: Dr. Rob Wüst, Dr. Todd Davenport, Dr. Flora Cornish, Hannah Davis, Dr. Letícia Soares, Gina Assaf, and Charlie McCone. Date: Thursday November 19, 10am PT / 1pm ET. Image description: Patient-Led Research Collaborative (PLRC) on a white background with soft, pastel-colored abstract shapes decorating the upper-right and lower-right corners. The colorful PLRC logo appears at the top left, followed by a bold black “Webinar” heading and the title “Clinical Trials, Biomarkers & Equitable Care in Long COVID” in large black text. A thin, multicolored gradient line separates the title from the event details: Thursday, November 19, 1–2:30 PM ET / 10–11:30 AM PT. Below are seven circular speaker headshots, each framed by a colorful gradient border and accompanied by names and affiliations. The top row features Dr. Todd Davenport (University of the Pacific), Dr. Rob Wüst (Vrije Universiteit Amsterdam), and Dr. Flora Cornish (The London School of Economics). The bottom row features Hannah Davis, Gina Assaf, Dr. Letícia Soares, and Charlie McCone, all representing PLRC. 06 Nov 2026 A new PLRC-funded study from UCSF looking at the post-hoc analysis of an mAb trial for #LongCovid shows how well-designed trials move the field forward, even when they have negative results. Participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to perceive treatment benefit based. Link to paper: https://www.nature.com/articles/s41467-026-77925-y 03 Nov 2026 Patient-Led Research Collaborative (PLRC) and RTHM Clinic released the Long COVID Treatment Guide earlier this year to support more informed conversations between patients and their clinicians. The guide covers over 30 different treatments. Today, we’re highlighting Ivabradine which has shown promise for Long COVID patients experiencing autonomic dysfunction, particularly those with postural orthostatic tachycardia syndrome (POTS). It works by lowering heart rate without significantly affecting blood pressure, which makes it especially relevant for people dealing with symptoms like tachycardia, dizziness, and exercise intolerance. This can be important for patients who are sensitive to medications that also lower blood pressure. Clinical studies and patient reports have shown that ivabradine can improve heart rate control and overall quality of life. Across studies, 60 to 78 percent of POTS patients have reported symptom improvement. Ivabradine should be discussed with a qualified clinician to determine whether it is appropriate for an individual case. This includes reviewing risks, contraindications, drug interactions, allergies, and potential side effects. The treatment guide is an evidence-grounded resource designed to support patients and clinicians in making informed decisions together. If you want a direct link to download the guide, comment #guide below, and we’ll send you a DM. 27 Oct 2026 Repeat COVID infections are never risk-free. Each one is another chance to get #LongCOVID. @nytimes’s Dani Blum explains why, with insights from Yale immunologist Dr. Akiko Iwasaki and WashU epidemiologist Dr. Ziyad Al-Aly. Read the full article: https://www.nytimes.com/2026/10/19/well/covid-reinfection-risks.html 19 Oct 2026 New @4youandme_org & PLRC paper in @jmirpub: a co-design framework for 5 patient-built health apps for complex diseases, including #LongCovid. Open code. Free for other teams to build on. For the #LongCovid app, PLRC led as the research partner organization, shaping the app, not just giving feedback on a product. Patient advocates from other orgs tailored app development and goals to their health conditions. 239 patients across 5 complex disease groups beta-tested the apps + wearables for up to 5 months. Retention: 92–100%. Patients stay engaged when the tool is actually built around them. Why it matters for Long COVID: symptoms are variable, fluctuating, and often dismissed clinically. This app lets patients track subjective symptoms alongside objective wearable data (HRV, sleep, activity) to surface personal patterns. Patients also pushed hard for customization — Long COVID doesn't look the same from person to person, so the app was built to flex to individual symptom presentations rather than force a single template. Full framework + code: https://mhealth.jmir.org/2026/1/e85425 A resource for Long COVID and other patient communities to build their own tools. 16 Oct 2026 Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support more informed conversations between patients and their clinicians. The guide covers over 30 different treatments. Today, we’re highlighting hyperbaric oxygen therapy (HBOT), which may be especially relevant for people with Long COVID experiencing cognitive impairment, fatigue, sleep issues, neuropsychiatric symptoms, or pain. In a randomized, double-blind, placebo-controlled trial of 73 people with Long COVID, 40 HBOT sessions led to significant improvements in attention, sleep quality, pain, and energy levels that persisted even one year after treatment. Echocardiogram assessment in the same group also showed a meaningful reduction in global longitudinal cardiac strain. A separate 10-patient study reported statistically significant improvements in fatigue and cognitive function after 10 HBOT sessions over 12 days. However, an interim safety analysis from an ongoing Karolinska Institute trial found that nearly half of participants experienced cough or chest discomfort during treatment, though it remains unclear whether those symptoms were related to HBOT or underlying Long COVID. In the Harvard/Stanford/OMF TREATME study, 38% of people with Long COVID who tried HBOT reported moderate to much better symptom improvement, though the Long COVID sample was small at 13 participants. Among people with ME/CFS, 25% reported moderate to much better improvement. HBOT should be discussed with a qualified clinician to determine whether it is appropriate for an individual case. The guide also notes that medical-grade HBOT can be expensive and time and energy consuming, and that claustrophobia can make treatment challenging. If you want a direct link to download the guide, comment #guide below, and we’ll send you a DM. 13 Oct 2026 You are not invisible. Share your story! Participate in the 2026 National Survey on Health and Disability (NSHD) conducted by the Institute for Health and Disability Policy Studies at the University of Kansas @ihdps_ku. Survey link: https://kuhealthsurvey.org Image description: [Slide 1] Image: Empty wheelchair sitting in nature. Text: Policymakers say people who aren't in data are invisible... You are not invisible! Share your story. 2026 National Survey on Disability (NSHD) kuhealthsurvey.org Phone: 1 855 556 6328 Email: [email protected] The University of Kansas Institute for Health and Disability Policy Studies [Slide 2] Imagen: Silla de ruedas vacía en plena naturaleza. Texto: Los responsables de formular políticas afirman que las personas que no figuran en los datos son invisibles... No eres invisible. ¡Comparte tu historia! 2026 Encuesta Nacional sobre Salud y Discapacidad (NSHD) kuhealthsurvey.org Teléfono: 1 855 556 6328 El correo: [email protected] The University of Kansas Institute for Health and Disability Policy Studies 12 Oct 2026 How do people with ME/CFS navigate gaps in medical knowledge about their illness? PLRC member Dr. Chloé de Canson explores how the “controversialisation” of ME, gaps in research (“undone science”), and medical ignorance have led patients to create their own systems for producing and sharing knowledge. Read more about the importance of patient-led research: https://www.sciencedirect.com/science/article/pii/S003936812600110X Image descriptions: [Slide 1] Why do people with ME claim to know more about the medical aspects of their disease than their doctors? Bc the mechanisms that ensure doctors' knowledge fail in the case of ME, and sick people have created mechanisms of knowledge production and dissemination to pick up the slack [Slide 2] In this paper, I cover what I call the 'controversialisation' of ME, the 'undone science' around it, the resulting production of ignorance or 'agnotology' among doctors, and the reactive lay production and distribution of knowledge among sick people. I am very proud to have interviewed and featured the words of amazing people w ME (or belonging to the IACC community), incl. kylofone, mecfsskeptic, TomKindlon, Naomi_D_Harvey, FvRhijn, Romatowski, organichemusic, betsyladyzhets, and tessfalor. Collectives of lay scientists like RenegadeRes and patientled are discussed. Several institutional researchers are mentioned but sunsopeningband and OpenMedF get a special mention for their work in collaboration with sick people. [Slide 3] I am also proud to have included discussions of two especially controversialised aspects of ME, an already controversialised disease. The first is the impact of mould on disease, which is thoroughly stigmatised, especially in left-wing and liberal circles: (article screenshot) [Slide 4] The second is the perhaps even more stigmatised fact of vaccine injuries. Vaccines are very safe and have played an essential role in massively reducing acute deaths from COVID, but in rare cases, they can trigger or worsen ME. Our community includes several vax-injured people. ...Continued in comments. 09 Oct 2026

Follower tracking

We have started recording @patientled, but only 1 observation so far — not enough to show a trend yet. Track it daily →

Download @patientled's data

Everything below is derived from this account, priced on the counts shown. Delivered as CSV by emailed link.

Every post & reel

305 posts & reels

$9.99

minimum

Caption, likes, comments, views, duration, mentions, co-authors and sponsored status for every post and reel.

See a sample
shortcodecaptionlikescomments
DbByCTHknGJPLRC is kicking off a summer fundraiser to help …
DVwHhqmGhGTThe Patient-Led Research Collaborative and the R…
DV6aO0QlNAGFor #LongCovid Awareness Day, we're releasing th…

Real rows from this account. The file continues in the same shape.

Everyone who follows them

up to 7,983 followers

$39.92

Handle, full name, ID, and verified/private flags for each follower.

See the columns
usernamefull_nameuser_idis_verifiedis_privateprofile_pic_url

These are the columns. We can't show live rows: Instagram serves no follower or following list to a logged-out client, so we hold none until you order.

Everyone they follow

up to 1,598 accounts

$9.99

minimum

Every account this one follows, same fields.

See the columns
usernamefull_nameuser_idis_verifiedis_privateprofile_pic_url

These are the columns. We can't show live rows: Instagram serves no follower or following list to a logged-out client, so we hold none until you order.

Counts are the maximum available today. If an export comes back smaller, we review it and contact you about the difference. Counts as last collected 4 days, 19 hours ago.

Tracking

A monthly plan, not a download: we keep reading @patientled and email you what changed.

Track @patientled every day · up to 5 accounts

We read @patientled daily from today and email you the week's follower, following and post changes, with every reading so far as a CSV. Add up to 4 more accounts on the same plan. Cancel any time.

See the columns
read_atfollowersfollowingpostsfollowers_change

These are the columns of the file. It gets one row per account for every day we read it, from the day you start.

$14.99/month